Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Comment by Stocktreeon Oct 16, 2016 11:50am
113 Views
Post# 25348574

RE:Stocktree, this is from MD &D March 27, 2014, page 4-5

RE:Stocktree, this is from MD &D March 27, 2014, page 4-5Sorry Josh, but as I read that, no 10% MB was sated to be achieved. It only speak about the initial goals of the trial and, based on the interim data, how many patients would be required to prove such an improvement.

On the rest of your post, I'll have to look at it more closely later today. But on your theory about the timing of the treatment, if we rely on the company's statements, we were told that the treatment proved to be more beneficial for sicker patients, so... 

In a sense, even if the trial had been the success they were looking for (20%MB), we could se an unethical dimension to it, but only to a certain point, and not unlike what any other trial could be associated with. But since it was considered unproven, giving patients the SOC and administrating them the PMX treatment once they reached 3 organ failure would not have been unethical, since it only gave them an additional chance at survival.

Unless I didn't get part of your argument. I have to say, I am pretty unwinded by all this affair and not proud about my lack of digging and blind trust in vague statements.
Bullboard Posts